Nocturne
Well-known member
http://www.jlr.org/content/early/2015/12/18/jlr.R051870.full.pdf
"In summary, the recent identification of genetic variants in LPA as being strongly associated with calcific aortic valve disease, and the Mendelian randomization studies demonstrating that this genetic association is mediated by circulating Lp(a), as well as our increased understanding of the mechanisms of Lp(a) and their potential role in atherogenesis and cardiovascular calcification, has reignited intense interest in Lp(a) in general, but also as a specific therapeutic target for calcific aortic valve disease. It is hoped that lowering of Lp(a) will demonstrate reduced progression of aortic valve disease and that targeted therapies directed at Lp(a) will become the preferred treatment for aortic valve disease in at risk individuals with high Lp(a) and, ultimately, will reduce the need for valve replacement and the costs and complications of CAVD."
Probably too late for me, as by the time these drugs clear the FDA (IF they clear the FDA), I'll likely have needed surgery (Lp(a) levels that are only a THIRD of mine present a 5X chance of being a "fast progressor" of CAVS) -- but maybe not too late for my kids!
"In summary, the recent identification of genetic variants in LPA as being strongly associated with calcific aortic valve disease, and the Mendelian randomization studies demonstrating that this genetic association is mediated by circulating Lp(a), as well as our increased understanding of the mechanisms of Lp(a) and their potential role in atherogenesis and cardiovascular calcification, has reignited intense interest in Lp(a) in general, but also as a specific therapeutic target for calcific aortic valve disease. It is hoped that lowering of Lp(a) will demonstrate reduced progression of aortic valve disease and that targeted therapies directed at Lp(a) will become the preferred treatment for aortic valve disease in at risk individuals with high Lp(a) and, ultimately, will reduce the need for valve replacement and the costs and complications of CAVD."
Probably too late for me, as by the time these drugs clear the FDA (IF they clear the FDA), I'll likely have needed surgery (Lp(a) levels that are only a THIRD of mine present a 5X chance of being a "fast progressor" of CAVS) -- but maybe not too late for my kids!
